Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
This article was originally published in The Pink Sheet Daily
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
You may also be interested in...
In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.